Brandon Couillard
Stock Analyst at Wells Fargo
(4.13)
# 470
Out of 5,147 analysts
185
Total ratings
54.13%
Success rate
12.66%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $121.11 | +36.24% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $130.62 | +37.80% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $18.67 | +12.51% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.63 | +29.59% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $93.34 | +33.92% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $8.88 | +57.66% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $317.79 | +11.71% | 8 | Feb 11, 2026 | |
| WGS GeneDx Holdings | Upgrades: Overweight | $155 | $77.48 | +100.05% | 7 | Feb 9, 2026 | |
| TECH Bio-Techne | Maintains: Overweight | $70 → $76 | $58.34 | +30.27% | 3 | Feb 6, 2026 | |
| MLAB Mesa Laboratories | Maintains: Equal-Weight | $83 → $94 | $96.80 | -2.89% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $97.16 | +13.22% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $516.37 | +30.72% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,354.16 | +7.08% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.50 | +28.57% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $240 | $207.87 | +15.46% | 5 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $40.34 | +36.34% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $205 | $199.00 | +3.02% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $110 | $73.42 | +49.82% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $90 → $105 | $103.15 | +1.79% | 19 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $276.69 | +22.88% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $267.56 | +27.07% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $188.66 | +37.81% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $81.45 | -1.78% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $29.25 | -21.37% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.39 | +443.93% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.16 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $1.01 | +989.11% | 2 | Oct 13, 2017 |
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $121.11
Upside: +36.24%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $130.62
Upside: +37.80%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $18.67
Upside: +12.51%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.63
Upside: +29.59%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $93.34
Upside: +33.92%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $8.88
Upside: +57.66%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $317.79
Upside: +11.71%
GeneDx Holdings
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $77.48
Upside: +100.05%
Bio-Techne
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $58.34
Upside: +30.27%
Mesa Laboratories
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $96.80
Upside: -2.89%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $97.16
Upside: +13.22%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $516.37
Upside: +30.72%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,354.16
Upside: +7.08%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.50
Upside: +28.57%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $230 → $240
Current: $207.87
Upside: +15.46%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $40.34
Upside: +36.34%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $190 → $205
Current: $199.00
Upside: +3.02%
Dec 1, 2025
Initiates: Equal-Weight
Price Target: $110
Current: $73.42
Upside: +49.82%
Nov 24, 2025
Downgrades: Hold
Price Target: $90 → $105
Current: $103.15
Upside: +1.79%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $276.69
Upside: +22.88%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $267.56
Upside: +27.07%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $188.66
Upside: +37.81%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $81.45
Upside: -1.78%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $29.25
Upside: -21.37%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $2.39
Upside: +443.93%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.16
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $1.01
Upside: +989.11%